V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Quest Diagnostics Executive Compensation (FY25)

DGX · Executive and director compensation, fiscal 2022 to 2025

The paid brief on Quest Diagnostics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 7, 2026Latest filing (8-K): May 21, 2026
15 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Quest Diagnostics brief$1,500Get the executive brief
278 figures on this page: 267 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
Chief executive, fiscal 2025
◇
James Davis
Latest say-on-pay support
=
May 20, 2026
Chief executive pay ratio
◇
To the median employee

More on Quest Diagnostics

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — James Davis: $14,404,862 → $15,498,479 (7.6% higher)
Say-on-pay support: 90.9% → 92.4% (1.5 points higher)
CEO pay ratio: 242:1 → 275:1 (13.6% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Quest Diagnostics' chief executive and what were they paid?
James Davis, Chairman, Chief Executive Officer and President, received $15,498,479 in total compensation for fiscal 2025. Davis' total moved 7.6% higher from the $14,404,862 reported for fiscal 2024.
What was Quest Diagnostics' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 92.4% of votes cast for or against in favor at the meeting held May 20, 2026.
Which companies are in Quest Diagnostics' peer group?
The disclosed peer group includes Agilent Technologies, Inc., Baxter International Inc., Becton, Dickinson and Company, Boston Scientific Corporation and DaVita Inc., among others.
What is Quest Diagnostics' chief executive pay ratio?
The company reported a chief executive pay ratio of 275:1 for fiscal 2025, against median employee compensation of $56,427.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
James Davis
Chairman, Chief Executive Officer and President
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
James Davis
Chairman, Chief Executive Officer and President
◇—◇◇◇—◇◇
Michael Prevoznik
Senior Vice President and General Counsel
◇—◇◇◇—◇◇
Karthik Kuppusamy
Senior Vice President, Clinical Solutions
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
James Davis
Chairman, Chief Executive Officer and President
◇—◇◇◇—◇◇
Sam Samad
Executive Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Catherine Doherty
Executive Vice President, Regional Businesses
◇—◇◇◇—◇◇
Michael Prevoznik
Senior Vice President and General Counsel
◇—◇◇◇—◇◇
Karthik Kuppusamy
Senior Vice President, Clinical Solutions
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
James Davis
Chairman, Chief Executive Officer and President
◇—◇◇◇—◇◇
Sam Samad
Executive Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Catherine Doherty
Executive Vice President, Regional Businesses
◇—◇◇◇—◇◇
Karthik Kuppusamy
Senior Vice President, Clinical Solutions
◇—◇◇◇—◇◇
Michael Prevoznik
Senior Vice President and General Counsel
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Catherine DohertyPSU——————◇
Catherine DohertyOPTION——————◇
James DavisOPTION——————◇
James DavisPSU——————◇
Karthik KuppusamyOPTION——————◇
Karthik KuppusamyPSU——————◇
Michael PrevoznikPSU——————◇
Michael PrevoznikOPTION——————◇
Sam SamadOPTION——————◇
Sam SamadPSU——————◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Karthik KuppusamyOption◇—◇2/23/2033
RSU◇◇——
RSU◇◇——
Option◇—◇2/12/2035
Option◇—◇2/14/2034
RSU◇◇——
PSU◇◇——
PSU◇◇——
Michael PrevoznikOption◇—◇2/23/2033
RSU◇◇——
RSU◇◇——
Option◇—◇2/12/2035
RSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇2/14/2034
Catherine DohertyRSU◇◇——
Option◇—◇2/23/2033
RSU◇◇——
Option◇—◇2/12/2035
RSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇2/14/2034
Sam SamadOption◇—◇2/23/2033
RSU◇◇——
RSU◇◇——
Option◇—◇2/12/2035
Option◇—◇2/14/2034
RSU◇◇——
PSU◇◇——
PSU◇◇——
James DavisOption◇—◇2/23/2033
RSU◇◇——
RSU◇◇——
Option◇—◇2/12/2035
Option◇—◇2/14/2034
RSU◇◇——
PSU◇◇——
PSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Catherine Doherty
Executive Vice President, Regional Businesses · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Excise tax treatment◇
James Davis
Chairman, Chief Executive Officer and President · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Excise tax treatment◇
Karthik Kuppusamy
Senior Vice President, Clinical Solutions · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Michael Prevoznik
Senior Vice President and General Counsel · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Excise tax treatment◇
Sam Samad
Executive Vice President and Chief Financial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Excise tax treatment◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Timothy M. Ring
Lead independent director
◇◇————◇
Gary M. Pfeiffer
◇◇————◇
Denise M. Morrison
◇◇————◇
Vicky B. Gregg
◇◇————◇
Timothy L. Main
◇◇————◇
Luis A. Diaz, Jr
◇◇————◇
Wright L. Lassiter III
◇◇————◇
Tracey C. Doi
◇◇————◇
Robert B. Carter
◇◇————◇
James E. Davis and Timothy C. Wentworth served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Equity is delivered as restricted stock units.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Agilent Technologies, Inc. A
  • Baxter International Inc. BAX
  • Becton, Dickinson and Company BDX
  • Boston Scientific Corporation BSX
  • DaVita Inc. DVA
  • Henry Schein, Inc. HSIC
  • Hologic, Inc. HOLX
  • Illumina, Inc. ILMN
  • Laboratory Corporation of America Holdings LH
  • Owens & Minor, Inc. ACH
  • Revvity, Inc. RVTY
  • Stryker Corporation SYK
  • Tenet Healthcare Corporation THC
  • Zimmer Biomet Holdings, Inc. ZBH

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 20, 2026=◇◇◇
2024May 15, 2025=◇◇◇
2023May 16, 2024=◇◇◇
2022May 17, 2023=◇◇◇
2021May 18, 2022=◇◇◇
2020May 21, 2021=◇◇◇
2019May 19, 2020=◇◇◇
2018May 14, 2019=◇◇◇
2017May 15, 2018=◇◇◇
2016May 19, 2017=◇◇◇
2015May 23, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Quest Diagnostics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Quest Diagnostics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Quest Diagnostics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Quest Diagnostics' disclosed peer group is defensible, who names Quest Diagnostics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
278 figures on this page: 267 cited to the filing that reported them, 11 calculated from figures it prints.
267 cited to the filing
11 calculated from the filing

Documents cited

  1. 0001022079-26-000052
  2. 0001140361-26-013356
    2025 Director Compensation Table · 2025 Grants of Plan-Based Awards Table · 2025 Summary Compensation Table · Compensation Discussion and Analysis · and 1 more section
  3. 0001022079-25-000154
  4. 0000930413-25-001171
    2024 Summary Compensation Table
  5. 0001022079-24-000133
  6. 0000930413-24-001247
    2023 Summary Compensation Table
  7. 0001022079-23-000104
  8. 0000930413-23-001199
    Summary Compensation Table
  9. 0001022079-22-000079
  10. 0001022079-21-000097
  11. 0001022079-20-000120
  12. 0001022079-19-000144
  13. 0001022079-18-000129
  14. 0001022079-17-000141
  15. 0001022079-16-000289
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Quest Diagnostics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/DGX (accessed 2026).
Short form: data: Velarion

The paid brief for Quest Diagnostics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
15 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Quest Diagnostics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Quest Diagnostics discloses

The companies named in DGX's own disclosed peer group.

Agilent Technologies, Inc.Baxter International Inc.Becton, Dickinson and CompanyBoston Scientific CorporationDaVita Inc.Henry Schein, Inc.Hologic, Inc.Illumina, Inc.Laboratory Corporation of America HoldingsOwens & Minor, Inc.Revvity, Inc.Stryker CorporationTenet Healthcare CorporationZimmer Biomet Holdings, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy